Aardvark Therapeutics Reports Q3 GAAP EPS of -$0.88
Aardvark Therapeutics has released its third-quarter financial results, reporting a GAAP earnings per share (EPS) loss of $0.88. The company's liquidity position saw a decline during the quarter, with cash, cash equivalents, and short-term investments dropping to $60.3 million as of September 30, 2026, down from $73.9 million at the end of June 2026. Despite the reduction in cash reserves, the company indicated that its current operating plans are being managed against these existing liquid assets. The report highlights a period of continued capital consumption as the firm progresses through its clinical or operational stages.
Tickers: $AARD
Topics: cash_runway earnings financial_results